ClinicalTrials.gg
CompletedNCT05123196Updated Dec 22, 2025

Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy

A Phase 2 interventional study of MT-8554 and Placebo in Painful Diabetic Peripheral Neuropathy, sponsored by Tanabe Pharma Corporation. Completed at 33 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Tanabe Pharma Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of MT-8554, compared to placebo, in subjects with painful diabetic peripheral neuropathy.

02

Conditions studied

  • Painful Diabetic Peripheral Neuropathy
03

In context

Lead sponsor

Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with written consent
  2. Patients aged >=20 years at the time of consent
  3. Outpatients
  4. Patients with pain associated with peripheral symmetric polyneuropathy due to diabetes mellitus and pain lasting >=3 months on the first day of the run-in period. The patient should meet >=2 of the following criteria or nerve conduction studies showing abnormalities in at least one test item (Conduction velocity, amplitude, and latency) for at least two nerves by the first day of run-in period.

    • 1. Subjective symptoms* thought to be due to diabetic polyneuropathy
    • 2. Decreased or eliminated bilateral Achilles tendon reflexes
    • 3. Bilateral decreased vibratory sense of the medial malleolus (=\< 10 seconds with a C 128 tuning fork)

      *Subjective symptoms thought to be due to diabetic neuropathy meet the following 3 criteria.

    • Bilateral
    • Toe and plantar symptoms (Numbness, pain or dysesthesia)
    • Does not cause upper extremity symptoms alone
  5. Patients whose NRS during the run-in period is assessed for >=4 days of the 7 days immediately before the first day of the treatment period and whose baseline 24-hour mean NRS score is >=4 and =\<8.
  6. Patients whose rate of change in the 24-hour mean NRS score during the 7 days immediately before the first day of the treatment period is \<30%.
  7. Patients whose treatment for diabetes mellitus is consistent >=8 weeks before the run-in period, who can consistently maintain the treatment throughout the study period, and in whom the investigator (or sub-investigator) can determine that glycemic control is constant.

Exclusion criteria

Exclusion Criteria:

  1. Patients with pain, disease, or skin condition that, in the opinion of the investigator (or sub-investigator), would influence the evaluation of painful diabetic peripheral neuropathy.

    For example, if other pain is in the same location as painful diabetic peripheral neuropathy, or if the pain intensity of the other pain is greater than that of painful diabetic peripheral neuropathy, which in the opinion of the investigator (or sub-investigator) would impact the assessment of painful diabetic peripheral neuropathy.

  2. Patients who have had amputation of upper and lower limbs other than toes due to gangrene caused by impaired blood circulation.
  3. Patients who do not meet the criteria of prohibited concomitant drugs or restricted concomitant drugs.
  4. Patients with to acetaminophen or a history of hypersensitivity to acetaminophen.
  5. Patients with functional class III or IV symptoms of heart failure.
  6. History of myocardial infarction, congestive heart failure, unstable angina, or cerebrovascular disorder (excluding lacunar infarction) within 6 months prior to .
  7. Patients with major psychiatric disorder such as depression or anxiety disorder.
  8. Patients with drug abuse or a history of drug abuse.
  9. Patients with current or previous infection with (HIV), virus (HBV) or virus (HCV). However, patients with previous infection with hepatitis B virus who are HBsAg-negative are eligible.
  10. Patients with > 10.5%.
  11. Patients with poorly controlled hypertension (>= 180 mmHg systolic and/or >= 110 mmHg diastolic).
  12. Patients with \< 30 mL/min/1.73 m\^2.
  13. Patients with or ALT > 2.5*.
  14. Patients who answered "Yes " to any item of Columbia Suicide Severity Rating Scale within the past 12 months.
  15. Patients who have a concomitant or a history of malignancy. However, patients who have a history of malignancy but have not experienced recurrence for at least 5 years before informed consent (patients who have not experienced recurrence for at least 5 years after the last administration if the patients were receiving anticancer drugs) will be excluded.
  16. Male or female patients of who do not agree to use from the date of informed consent until 3 months after the completion (discontinuation) of product.
  17. Female patients who are pregnant, breastfeeding or possibly pregnant.
  18. Patients who participated in another clinical study and received investigational product within 12 weeks before informed consent.
  19. Prior exposure to MT-8554.
  20. Other patients who, in the opinion of the investigator (or sub-investigator), are ineligible for this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    MT-8554

    MT-8554 will be started from a low dose, and gradually increase the dose in order.

    Drug: MT-8554

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral Capsule

    Also known as: Elismetrep

  • DrugPlacebo

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Change from baseline in the weekly mean 24-hour average NRS score at Week 12 in treatment period

    Numeric Rating Scale (NRS) is the 11-point numerical rating scale of 0 (no pain) to 10 (worst possible pain). Higher NRS scores indicated worse outcome.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change from baseline in weekly mean 24-hour average NRS score at each assessment point

    Numeric Rating Scale (NRS) is the 11-point numerical rating scale of 0 (no pain) to 10 (worst possible pain). Higher NRS scores indicated worse outcome.

    Time frame: Up to Week 12

  2. Average weekly 24-hour NRS score during the 12 week treatment period 30% and 50% responder rates

    Numeric Rating Scale (NRS) is the 11-point numerical rating scale of 0 (no pain) to 10 (worst possible pain). Higher NRS scores indicated worse outcome.

    Time frame: Baseline and Week 12

  3. Change from baseline in weekly mean daily NRS score at each assessment point

    Numeric Rating Scale (NRS) is the 11-point numerical rating scale of 0 (no pain) to 10 (worst possible pain). Higher NRS scores indicated worse outcome.

    Time frame: Up to Week 12

  4. Change from baseline in weekly mean nocturnal average NRS score at each assessment point

    Numeric Rating Scale (NRS) is the 11-point numerical rating scale of 0 (no pain) to 10 (worst possible pain). Higher NRS scores indicated worse outcome.

    Time frame: Up to Week 12

  5. Change from baseline in weekly mean 24 hour worst NRS score at each assessment point

    Numeric Rating Scale (NRS) is the 11-point numerical rating scale of 0 (no pain) to 10 (worst possible pain). Higher NRS scores indicated worse outcome.

    Time frame: Up to Week 12

  6. Change from baseline in NPSI at each assessment point

    Neuropathic Pain Symptom Inventory (NPSI) is the questionnaire to evaluate the different symptoms of neuropathic pain and each symptoms are evaluated from 0 (no pain) to 10 (worst possible pain). Higher NPSI scores indicated worse outcome.

    Time frame: Up to Week 12

  7. Change from baseline in BPI pain severity at each assessment point

    Brief Pain Inventory (BPI) is the questionnaire to assess the severity of pain from 0 (no pain) to 10 (pain as bad as patient can imagine). Higher BPI scores indicated worse outcome.

    Time frame: Up to Week 12

  8. Change from baseline in BPI functional impairment at each assessment point

    Brief Pain Inventory (BPI) is the questionnaire to assess the impact of pain on daily functions from 0 (does not interfere) to 10 (completely interferes). Higher BPI scores indicated worse outcome.

    Time frame: Up to Week 12

  9. Change from baseline in MOS-SS at each assessment point

    Medical Outcomes Study-Sleep Scale (MOS-SS) is the questionnaire to evaluate the "sleep disorder " "snoring" "sleep arousal with shortness of breath or headache" "sleep sufficiency" "somnolence" and "amount of sleep/optimal sleep" ranges from 0 (all of the time) to 6 (none of the time). Lower MOS-SS scores indicated worse outcome.

    Time frame: Up to Week 12

  10. Proportion of PGIC responders at each assessment point

    Patient Global Impression of Change (PGIC) is a questionnaire to evaluate the overall impression of pain improvement by patient from 1 (very much improved) to 7 (very much worse). Higher PGIC scores indicated worse outcome.

    Time frame: Up to Week 12

  11. Proportion of CGIC responder at each assessment point

    Clinician Global Impression of Change (CGIC) a questionnaire to evaluate the overall impression of pain improvement by clinician from 1 (very much improved) to 7 (very much worse). Higher CGIC scores indicated worse outcome.

    Time frame: Up to Week 12

07

Study locations

33 sites
  • Yachiyo Hospital
    Anjo, Aichi-ken 446-8510, Japan
  • Japan Organization of Occupational Health and Safety Chubu Rosai Hospital
    Nagoya, Aichi-ken 455-8530, Japan
  • JUNEIKAI Medical Corporation Akaicho Clinic
    Chiba, Chiba 260-0804, Japan
  • Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital
    Fukuoka, Fukuoka 811-0213, Japan
  • TOJITAMA thyroid and diabetes Clinic
    Fukuoka, Fukuoka 815-0033, Japan
  • Kunisaki Makoto Clinic
    Fukuoka, Fukuoka 819-0168, Japan
  • Steel Memorial Yawata Hospital
    Kitakyushu-shi, Fukuoka 805-0050, Japan
  • Medical Corporation Kouhoukai Takagi Hospital
    Okawa-shi, Fukuoka 831-0016, Japan
  • Matsunami Health Promotion Clinic
    Hashima-gun, Gifu 501-6061, Japan
  • Kikuchi Clinic of Internal Medicine
    Maebashi, Gunma 370-3573, Japan
  • Japanese Red Cross Asahikawa Hospital
    Asahikawa, Hokkaido 070-8530, Japan
  • Hakodate Central General Hospital
    Hakodate, Hokkaido 040-8585, Japan
  • Jiyugaoka Yamada Internal Medicine Clinic
    Obihiro, Hokkaido 080-0848, Japan
  • Sanuki Municipal Hospital
    Sanuki-shi, Kagawa-ken 769-2393, Japan
  • Takamatsu Red Cross Hospital
    Takamatsu, Kagawa-ken 760-0017, Japan
  • Shonan Fujisawa Tokushukai Hospital
    Fujisawa-shi, Kanagawa 251-0041, Japan
  • Shunkaikai Inoue Hospital
    Nagasaki, Nagasaki 850-0045, Japan
  • Medical Corporation Keiaikai Nakamura Hospital
    Beppu, Oita Prefecture 874-0937, Japan
  • Medical Corporation Ikeikai Inobe Funai Clinic
    Ōita, Oita Prefecture 870-0021, Japan
  • Abe Diabetes Clinic
    Ōita, Oita Prefecture 870-0039, Japan
  • Saiki Central Hospital
    Saiki, Oita Prefecture 876-0851, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita, Osaka 565-0853, Japan
  • Hisatomi Clinic
    Saga, Saga-ken 849-0937, Japan
  • Soka Sugiura Internal Medicine Clinic
    Sōka, Saitama 340-0034, Japan
  • OMI MEDICAL CENTER, Social Medical Corporation Seikoukai
    Kusatsu, Shiga 525-8585, Japan
  • Kumanomae Nishimura Naika Clinic
    Arakawa-ku, Tokyo 116-0012, Japan
  • Tokyo Center Clinic
    Chuo-ku, Tokyo 103-0028, Japan
  • Sugawara Clinic
    Nerima-ku, Tokyo 177-0041, Japan
  • Ome Municipal General Hospital
    Ome-shi, Tokyo 198-0042, Japan
  • Medical Corporation Souaikai Aihara Medical Clinic
    Shinagawa-ku, Tokyo 142-0053, Japan
  • Medical Corporation Heishinkai ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • Japan Organization of Occupational Health and Safety Sanin Rosai Hospital
    Yonago, Tottori 683-8605, Japan
  • Kitano Hospital, Tazuke Kofukai Medical Research Institute
    Osaka, 530-8480, Japan
08

References and documents

Individual participant data

Plan to share: Yes — When requested by a qualified researcher in the field of science or medicine, Tanabe Pharma Corporation will share clinical trial data that was collected from individual patients in a clinical trial with that researcher after a review committee of experts determines that such sharing is appropriate. Access Criteria: Please refer to the following link for conditions and limitations for sharing data. URL: https://www.tanabe-pharma.com/en/develop/protocol.html

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Nov 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2021
First posted
Nov 17, 2021
StartActual
Nov 16, 2021
Primary completionActual
Nov 1, 2022
CompletionActual
Nov 8, 2022
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05123196
Responsible party
Sponsor
First posted
Nov 17, 2021
Start date
Nov 16, 2021
Primary completion
Nov 1, 2022
Completion
Nov 8, 2022
Last update
Dec 22, 2025

Study contacts

General Manager
study director · Tanabe Pharma Corporation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion